Clinical course and outcomes of 344 intensive care patients with COVID-19

American Journal of Respiratory and Critical Care Medicine

Volumn 201, Issue 11, 2020, Pages 1430-1434

  Wang, Yang ^a   Lu, Xiaofan ^b   Li, Yongsheng ^c   Chen, Hui ^d   Chen, Taige ^e   Su, Nan ^d   Huang, Fang ^d   Zhou, Jing ^f   Zhang, Bing ^a   Yan, Fangrong ^b   Wang, Jun ^d  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^e MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^f THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; IMMUNOGLOBULIN; MUSCLE RELAXANT AGENT; MYOGLOBIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; CLINICAL OUTCOME; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; CREATINE KINASE BLOOD LEVEL; CRITICALLY ILL PATIENT; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; EXTRACORPOREAL OXYGENATION; FEMALE; HEART MUSCLE INJURY; HUMAN; INTENSIVE CARE; LETTER; LIVER INJURY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NONINVASIVE VENTILATION; OXYGEN THERAPY; PRIORITY JOURNAL; RHABDOMYOLYSIS; SEPTIC SHOCK; SURVIVOR; AGE; AGED; BETACORONAVIRUS; CHINA; CORONAVIRUS INFECTION; CRITICAL ILLNESS; MIDDLE AGED; MORTALITY; PANDEMIC; PATHOPHYSIOLOGY; RISK FACTOR; VIRUS PNEUMONIA; BREATHING RATE; COMORBIDITY; FATALITY; INCIDENCE; LYMPHOCYTE COUNT; SURVIVAL ANALYSIS;

AGE FACTORS; AGED; BETACORONAVIRUS; CHINA; CORONAVIRUS INFECTIONS; CRITICAL CARE; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; PANDEMICS; PNEUMONIA, VIRAL; RISK FACTORS;

EID: 85083166700     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.202003-0736LE     Document Type: Letter

References (15)

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al.; China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med [online ahead of print] 28 Feb 2020; DOI: 10.1056/NEJMoa2002032.
2. Jamil S, Mark N, Carlos G, Dela Cruz CS, Gross JE, Pasnick S. Diagnosis and management of COVID-19 disease [abstract]. Am J Respir Crit Care Med [online ahead of print] 30 Mar 2020; DOI: 10.1164/rccm.2020C1.
3. National Health Commission of the People’s Republic of China. Chinese management guideline for COVID-19 (version 6.0) [in Chinese]. [posted 2020 Feb 18; accessed 2020 Feb 19]. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/ b218cfeb1bc54639af227f922bf6b817.pdf.
4. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801–810.
5. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al.; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307: 2526–2533.
6. Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, et al.; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost [online ahead of print] 4 Feb 2013; DOI: 10.1111/jth.12155.
7. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA [online ahead of print] 24 Feb 2020; DOI: 10.1001/jama.2020.2648.
8. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med [online ahead of print] 24 Feb 2020; DOI: 10.1016/S2213-2600(20)30079-5. [Published erratum appears in Lancet Respir Med 8:e26.]
9. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 2004;25:291–294.
10. Riviello ED, Kiviri W, Twagirumugabe T, Mueller A, Banner-Goodspeed VM, Officer L, et al. Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali modification of the Berlin definition. Am J Respir Crit Care Med 2016;193: 52–59.
11. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020:102763.
12. Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014;160:389–397.
13. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015;28:465–522.
14. Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep 2007;8: 1142–1148.
15. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology [online ahead of print] 26 Feb 2020; DOI: 10.1148/radiol.2020200642.